Drugs & Targets FDA, Flatiron Health renew five-year research collaboration on real-world data September 15, 2023Vol.49 No.34
Drugs & Targets FDA establishes Oncology Quality, Characterization and Assessment of Real-World Data Initiative June 30, 2023Vol.49 No.26
Clinical Roundup Research finds ECOG scores restrict patient access to trials, preventing trials from accurately representing real-world patients February 24, 2023Vol.49 No.08
FreeGuest Editorial S2302 Pragmatica-Lung Trial: Reaching more representative groups of patients with exciting clinical trials December 21, 2022Vol.48 No.46By Jhanelle E. Gray, Karen Reckamp, Mary Redman, Konstantin H. Dragnev, Ellen V. Sigal, Shakun Malik, Meg Mooney, James H. Doroshow and Charles D. Blanke
Conversation with The Cancer Letter FDA’s Singh and Rivera describe the “new normal”—and the future—in cancer pragmatic trials December 09, 2022Vol.48 No.44By Jacquelyn Cobb, Matthew Bin Han Ong and Paul Goldberg
Regulatory News ODAC considers the first application based wholly on RWE methodology—and nixes it unanimously November 04, 2022Vol.48 No.40By Paul Goldberg
Conversation with The Cancer Letter Flatiron CEO Carolyn Starrett: We’re reimagining the infrastructure of cancer care, and we’re going global July 29, 2022Vol.48 No.30By Matthew Bin Han Ong
Clinical Roundup Real-world data show potential of Cosela to reduce myelosuppression in ES-SCLC treated with chemo April 08, 2022Vol.48 No.14
